GYRE THERAPEUTICS, INC.GYREEarnings & Financial Report
Nasdaq
NextMar 17, 2026
GYRE Q3 2025 Key Financial Metrics
Revenue
$30.6M
Gross Profit
$28.9M
Operating Profit
$6.9M
Net Profit
$5.9M
Gross Margin
94.7%
Operating Margin
22.7%
Net Margin
19.4%
YoY Growth
19.9%
EPS
$0.03
Financial Flow
GYRE THERAPEUTICS, INC. Q3 2025 Financial Summary
GYRE THERAPEUTICS, INC. reported revenue of $30.6M for Q3 2025, with a net profit of $5.9M (19.4% margin). Cost of goods sold was $1.6M, operating expenses totaled $22.0M.
Key Financial Metrics
| Total Revenue | $30.6M |
|---|---|
| Net Profit | $5.9M |
| Gross Margin | 94.7% |
| Operating Margin | 22.7% |
| Report Period | Q3 2025 |
GYRE THERAPEUTICS, INC. Annual Revenue by Year
GYRE THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $105.8M).
| Year | Annual Revenue |
|---|---|
| 2024 | $105.8M |
| 2023 | $113.5M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27.1M | $27.2M | $25.2M | $25.5M | $27.9M | $22.1M | $26.8M | $30.6M |
| YoY Growth | N/A | 9.0% | -14.0% | -20.5% | 2.7% | -18.8% | 6.1% | 19.9% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $116.5M | $122.0M | $120.9M | $125.2M | $125.4M | $129.8M | $152.6M | $159.4M |
| Liabilities | $38.1M | $33.2M | $27.6M | $26.8M | $27.0M | $25.5M | $23.2M | $22.0M |
| Equity | $-15.8M | $56.6M | $60.4M | $63.2M | $63.3M | $68.1M | $92.0M | $101.9M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $37.8M | $2.9M | $-5.5M | $1.7M | $-2.8M | $-129000 | $2.1M | $4.7M |